FDA OKs Lurasidone for Use as Bipolar Medication in Children
March 7th 2018Officials with the FDA have approved a supplemental new drug application (sNDA) to expand the use of lurasidone HCl (Latuda, Sunovion) to include the treatment of bipolar depression in pediatric patients (10 to 17 years of age).
Read More
Practice Pearls from the 2018 Clostridium Difficile Treatment Guidelines
March 6th 2018The IDSA and SHEA have made a recent update to the previously published practice guidelines for CDI. While many of the recommendations remain the same, there are a few key changes that the update has addressed.
Read More
Low Risk of Safety, Efficacy Concerns After Switching to a Biosimilar
March 6th 2018In an effort to evaluate whether switching from a reference biologic to a biosimilar could lead to altered clinical outcome, a research team, led by Hillel Cohen, PhD, conducted a systematic literature review of all available switching studies.
Read More